# Parker Institute for Cancer Immunotherapy

> Parker Institute for Cancer Immunotherapy is a VC fund backing Biotechnology. See 18 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: San Francisco, United States
- Total investments: 18
- Last investment: Jul 2025
- Lead investor: 28%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/7942549/
- X (Twitter): https://twitter.com/parkerici
- Website: https://www.parkerici.org/
- Facebook: https://www.facebook.com/ParkerICI/

Parker Institute for Cancer Immunotherapy is a VC fund in San Francisco focused on Biotechnology and Health Care. The Parker Institute for Cancer Immunotherapy brings together the best scientists, clinicians, and industry partners. The company strives to build a smarter and more coordinated cancer immunotherapy research effort to save lives.

## Contacts

5 contacts available for Parker Institute for Cancer Immunotherapy. Shizune tracks 11 team members at Parker Institute for Cancer Immunotherapy. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/parker-institute-for-cancer-immunotherapy?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 10 | 56% |
| Health Care | 8 | 44% |
| Therapeutics | 7 | 39% |
| Medical | 3 | 17% |
| Genetics | 1 | 6% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 5 | 28% |
| Funding Round | 2 | 11% |
| Seed | 1 | 6% |
| Grant | 1 | 6% |
| Series B | 1 | 6% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 9 | 50% |
| United Kingdom | 1 | 6% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Jeffrey Bluestone | President & CEO | 1 | https://shizune.co/investors/profile/jeffrey-bluestone |
| Sean Parker | Founder and Chairman | 25 | https://shizune.co/investors/profile/sean-parker |
| Charles Michael Yim | Donor | 0 | https://shizune.co/investors/profile/charles-michael-yim |
| Crystal Mackall | Director, Parker Institute for Cancer Immunotherapy at Stanford | 0 | https://shizune.co/investors/profile/crystal-mackall |
| Crystal Mackall | Director, Parker Institute for Cancer Immunotherapy at Stanford | 0 | https://shizune.co/investors/profile/crystal-mackall-ab0b |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Dispatch Bio | Dispatch Bio helps create a world where all cancer patients can be cured. | $216M | Series A | Jul 23, 2025 |  |
| ArsenalBio | ArsenalBio is building a programmable cell therapy company to create highly effective and accessible immune cell therapies to impact outcomes for a much broader number of patients, initially those with cancer. Founded in 2019, ArsenalBio is focused on integrating technologies such as CRISPR-based genome engineering, scaled and high throughputtarget identification, synthetic biology, and machine learning to advance a new paradigm to discover and develop immune cell therapies. With its programmable and computationally driven approach, ArsenalBio aspires to evolve critical metrics of success for immune cell therapies, including enhanced and broader efficacy, increased patient safety, reduced provider costs and expanded market access. | $325M | Series C | Sep 04, 2024 |  |
| Xaira Therapeutics | Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease. The company seeks to rethink the drug discovery and development process from end-to-end by bringing together leading talent across three core areas: machine learning research tobetter understand biology, expansive data generation to power new models, and robust therapeutic product development to treat disease. Xaira is headquartered in the San Francisco Bay Area. | $1B |  | Apr 23, 2024 |  |
| Xaira Therapeutics | Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease. The company seeks to rethink the drug discovery and development process from end-to-end by bringing together leading talent across three core areas: machine learning research tobetter understand biology, expansive data generation to power new models, and robust therapeutic product development to treat disease. Xaira is headquartered in the San Francisco Bay Area. | $1B | Series A | Apr 23, 2024 |  |
| Azalea Therapeutics | Azalea Therapeutics is a biotechnology company pioneering precision genome engineering directly inside the body, with a primary focus on developing cancer immunotherapies. Their innovative approach uses Envelope Delivery Vehicles (EDVs) to selectively locate and deliver genome editing tools to T cells within the patient, enabling the engineering ofthese cells in vivo rather than ex vivo (outside the body). This method aims to transform the patient’s own T cells into powerful cancer therapies safely and efficiently. | $1M | Grant | Oct 01, 2023 |  |
| Georgiamune | Georgiamune is a biotechnology company developing next-generation immunotherapeutics for cancer and autoimmune diseases. | $75M | Series A | Aug 09, 2023 |  |
| Georgiamune | Georgiamune is a biotechnology company developing next-generation immunotherapeutics for cancer and autoimmune diseases. | $75M | Series A | Aug 09, 2023 |  |
| Akamis Bio | Akamis Bio is a clinical-stage oncology company whose mission is to use its groundbreaking Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to improve the lives of cancer patients. To accomplish this goal, the company is developing a portfolio of solid tumor-targeted T-SIGn® therapeutics that will allow a patient's immune system torecognize, attack, and clear their cancer. | $30M | Debt Financing | Jan 05, 2023 |  |
| Akamis Bio | Akamis Bio is a clinical-stage oncology company whose mission is to use its groundbreaking Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to improve the lives of cancer patients. To accomplish this goal, the company is developing a portfolio of solid tumor-targeted T-SIGn® therapeutics that will allow a patient's immune system torecognize, attack, and clear their cancer. | $30M | Convertible Note | Jan 05, 2023 |  |
| ArsenalBio | ArsenalBio is building a programmable cell therapy company to create highly effective and accessible immune cell therapies to impact outcomes for a much broader number of patients, initially those with cancer. Founded in 2019, ArsenalBio is focused on integrating technologies such as CRISPR-based genome engineering, scaled and high throughputtarget identification, synthetic biology, and machine learning to advance a new paradigm to discover and develop immune cell therapies. With its programmable and computationally driven approach, ArsenalBio aspires to evolve critical metrics of success for immune cell therapies, including enhanced and broader efficacy, increased patient safety, reduced provider costs and expanded market access. | $220.8M | Series B | Sep 06, 2022 |  |

10 of 18 investments shown.

## Co-investors
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 7 deals together
- [Westlake Village BioPartners](https://shizune.co/investors/profile/westlake-village-biopartners) — VC Fund, 5 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 4 deals together
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund, 4 deals together
- [Kleiner Perkins](https://shizune.co/investors/profile/kleiner-perkins-caufield-byers) — VC Fund, 4 deals together
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund, 4 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Parker Institute for Cancer Immunotherapy invest in?

Parker Institute for Cancer Immunotherapy invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Funding Round stage. Most of the 18 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Parker Institute for Cancer Immunotherapy?

Public channels for Parker Institute for Cancer Immunotherapy include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Parker Institute for Cancer Immunotherapy?

The team at Parker Institute for Cancer Immunotherapy includes Jeffrey Bluestone (President & CEO), Sean Parker (Founder and Chairman) and Charles Michael Yim (Donor), among 11 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co